PARP1 and small cell lung carcinoma: To note, olaparib plus durvalumab (anti-PD-L1) showed a dismal overall response rate (ORR) of 10% (n = 2 patients) in 19 evaluable patients with relapsed SCLC treated in a phase II trial [77], suggesting that the combination of an agent directly inducing DNA damage with a PARP inhibitor might be more effective for SCLC treatment.